| Bioactivity | AZD3264 is a selective IkB-kinase IKK2 inhibitor. | ||||||||||||
| In Vivo | AZD3264 is a selective IkB-kinase IKK2 inhibitor, which is currently in preclinical development for the potential treatment of chronic pulmonary obstructive disorder (COPD) and asthma[1]. | ||||||||||||
| Name | AZD3264 | ||||||||||||
| CAS | 1609281-86-8 | ||||||||||||
| Formula | C21H23N5O4S | ||||||||||||
| Molar Mass | 441.50 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Andiappan Murugan, et al. Exploiting the Differential Reactivities of Halogen Atoms: Development of a Scalable Route to IKK2 Inhibitor AZD3264. Org Process Res Dev. 2014 Apr 29;18(5): 646-651. |